Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)

NCT07525258 | Not Yet Recruiting

• 2 other identifiers: 20000387991K23AA031334-01
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with AUD and ALD hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can help more patients have access to it.

Conditions

Alcohol Use Disorder; Alcohol-associated Liver Disease

Keywords

Clinicians; Medications for Alcohol Use Disorder

Outcome Measures

Primary Outcomes (4)

• Recruitment success to assess Feasibility

  Percentage of clinicians enrolled out of all recruited

  3, 6 and 12 months

• Educational Workshop Attendance to assess Feasibility

  Percentage of clinicians that attend the educational workshops

  3, 6 and 12 months

• Clinician Decision Support Tool Use to assess Feasibility

  Percentage of visits involving patients with AUD and ALD in which the clinical decision support tool is used

  3, 6 and 12 months

• Acceptability of Intervention Measure (AIM) to assess Acceptability

  4-item measure of perceived intervention acceptability. Total score 1-5 with higher scores indicating greater acceptability

  3, 6 and 12 months

Study Arms (1)

Hepatology Clinicians

EXPERIMENTAL

Clinician participants will participate in a multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested. Participants will attend two approximately 60-minute-long educational sessions in which key points related to AUD treatment based on the HPCR resource and implementation facilitation intervention will be reviewed.

Behavioral: Implementation Intervention

Interventions

Implementation Intervention BEHAVIORAL

A multipronged intervention including hepatology clinician education, patient education, clinical decision support, and clinician audit and feedback which will be adapted and tested.

Hepatology Clinicians

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.

You may not qualify if:

• Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.

Sponsors & Collaborators

• Yale University: lead
• National Institute on Alcohol Abuse and Alcoholism (NIAAA): collaborator

Study Sites (1)

Yale School of Medicine/Yale-New Haven Health

New Haven, Connecticut, 06520, United States

Location

MeSH Terms

Conditions

Alcoholism

Condition Hierarchy (Ancestors)

Alcohol-Related Disorders; Substance-Related Disorders; Chemically-Induced Disorders; Mental Disorders

Study Officials

• Lamia Haque

  Yale University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lamia Haque, MD MPH

CONTACT

(203) 777-0304; lamia.haque@yale.edu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Hepatology clinicians from across Yale-affiliated outpatient hepatology practices, including attending physicians, trainees, and advanced practice providers

Study Record Dates

• First Submitted: April 6, 2026
• First Posted: April 13, 2026
• Study Start: April 1, 2026
• Primary Completion (Estimated): April 1, 2029
• Study Completion (Estimated): April 1, 2029
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)